Zhejiang Taimei Medical Technology Co., Ltd. (“Taimei Medical”, HKEX: 02576) announced that its Board resolved on 18 May 2026 to introduce an H-Share Award Scheme (Existing Shares).

The initiative aims to strengthen the company’s long-term incentive framework by aligning employee interests with those of shareholders and the company’s sustainable development goals. Awards will be satisfied solely with existing H shares; no new shares will be issued.

Regulatory status: • The plan is classified as a “share scheme involving existing shares” under Chapter 17 of the Hong Kong Listing Rules and falls within Rule 17.12. • Because it does not involve new share issuance, it is exempt from shareholder approval under the Listing Rules. • Nonetheless, Taimei Medical’s Articles of Association require shareholder endorsement via special resolutions, so the proposal will be tabled at an upcoming extraordinary general meeting (EGM).

Next steps: • A circular detailing the H-Share Award Scheme and the EGM notice will be dispatched in due course. • The company advises shareholders and potential investors to exercise caution when dealing in its securities until the EGM outcome is known.

Board composition (as of the announcement date): Executive Directors – Dr. Zhao Lu (Chairman), Ma Dong, Zhang Hongwei, Lu Yiming, Huang Yufei, Ni Xiaomei Independent Non-executive Directors – Dr. Jiang Xiao, Dr. Li Zhiguo, Fung Che Wai Anthony